Immunomedics (IMMU) Rating Lowered to Sell at ValuEngine

Immunomedics (NASDAQ:IMMU) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Monday, December 4th.

Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Jefferies Group raised their target price on shares of Immunomedics from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Finally, BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $15.33.

Immunomedics (IMMU) traded down $0.16 on Monday, reaching $16.16. 4,163,863 shares of the company’s stock were exchanged, compared to its average volume of 4,162,736. The company has a debt-to-equity ratio of -0.29, a current ratio of 0.74 and a quick ratio of 0.74. Immunomedics has a twelve month low of $3.30 and a twelve month high of $17.05. The stock has a market cap of $2,480.98, a price-to-earnings ratio of -7.25 and a beta of 1.51.

In other news, Director Venbio Select Advisor Llc purchased 1,150,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Behzad Aghazadeh purchased 1,325,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average price of $10.47 per share, with a total value of $13,872,750.00. The disclosure for this purchase can be found here. 6.60% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC increased its holdings in shares of Immunomedics by 260.6% during the 2nd quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock worth $48,537,000 after buying an additional 3,972,388 shares during the last quarter. State Street Corp increased its holdings in shares of Immunomedics by 37.2% during the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock worth $42,549,000 after buying an additional 1,305,298 shares during the last quarter. Vanguard Group Inc. increased its holdings in Immunomedics by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,522,091 shares of the biopharmaceutical company’s stock valued at $39,930,000 after purchasing an additional 105,558 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Immunomedics by 1.7% in the 2nd quarter. Farallon Capital Management LLC now owns 4,227,500 shares of the biopharmaceutical company’s stock valued at $37,329,000 after purchasing an additional 72,500 shares during the last quarter. Finally, Palo Alto Investors LLC acquired a new stake in Immunomedics in the 2nd quarter valued at approximately $26,582,000. Institutional investors and hedge funds own 76.28% of the company’s stock.

WARNING: This article was first published by Week Herald and is the property of of Week Herald. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://weekherald.com/2017/12/30/immunomedics-immu-cut-to-sell-at-valuengine.html.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply